Skip to content
drillr.ai

NTRA

Natera, Inc.

NASDAQ · USHealthcareMedical - Diagnostics & Research
$262.63-3.23%

Price as of Jul 20, 2026

NTRA news

Natera, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio

    Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54572158&newsitemid=20260716661899&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=cb599037709525a7bf5276365f957cfb) (NASDAQ: NTRA

    Business Wire ·

  2. Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

    Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54567708&newsitemid=20260709678126&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=a52bb05efd15731b67dda17facf2d2d5) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today

    Business Wire ·

  3. Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

    Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending final reimbursement and pricing Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54559458&newsitemid=20260623359315&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=d8350ed8f0588d8bfdb20a8e799f9d48) (NASDAQ:

    Business Wire ·

  4. NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

    NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC) Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54558680&newsitemid=2

    Business Wire ·

  5. Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

    Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54556267&newsitemid=20260618969671&lan=en-US&anchor=Natera%2C+Inc.&index=89&md5=78f0769935dd1625dc92c1f0505bb81f) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine,

    Business Wire ·

  6. Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

    Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos’ Phase I/II trial Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54543832&newsitemid=20260529102657&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=cc04d22ce6d076764d04795c1457e276) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicin

    Business Wire ·

  7. Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

    Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer Signatera(™) will be used to identify patients who may be able to delay or defer adjuvant CDK4/6 inhibitor therapy in intermediate-risk HR+/HER2- breast cancer SIGNAL is a new group of Natera-sponsored interventional trials designed to establish the clinical utility of MRD-guided treatment de-escalation strategies across multiple cancer types Natera, Inc. (https:/

    Business Wire ·

  8. Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

    Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology Overall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscape Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54540493&newsitemid=20260521853793&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=ac6eae73560f54cc2294351bdb1a8c51) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landma

    Business Wire ·

  9. Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

    Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera’s Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling precision interventions for MRD-positive patients while sparing MRD-negative patients from potentially unnecessary treatment Natera, Inc. (https://cts.businesswire.com/ct/CT?id=

    Business Wire ·

  10. Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54497158&newsitemid=20260413928881&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=f448fde73d95909f2b39dd4e1f022dfc) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis

    Business Wire ·

  11. Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

    Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54488369&newsitemid=20260409795411&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=a676775f449fc320caf205f5f5db74dd) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera’s litiga

    Business Wire ·

  12. 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

    20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform Data from >75,000 patients underscore advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and continued expansion of MRD and other capabilities Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54481226&newsitemid=20260407837545&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=473dd7bbbe673854b9642a175df28217) (NASDAQ: NTRA)

    Business Wire ·

  13. SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

    Signatera(TM) MRD Identifies Breast Cancer Patients Who Can Forgo Surgery Prospective study published in Clinical Cancer Research shows that women >70 who tested Signatera MRD-negative could avoid surgery and remain progression-free Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54473359&newsitemid=20260331738825&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=b57eaaa675fd9fc05c00700b5d74675b) (NASDAQ: NTRA), a global leader in cell-free DNA and

    Business Wire ·

  14. Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

    Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers New findings show that Signatera status can help identify high-risk patients and inform non-operative management and surveillance strategies Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54448496&newsitemid=20260316838962&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=05ec376d8763998d5efc685846d020a9) (NASDAQ: NTRA), a global leader in cell-free DNA and precisi

    Business Wire ·

  15. Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

    Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation 11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancers Natera, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.natera.com&esheet=54435003&newsitemid=20260227178662&lan=en-US&anchor=Natera%2C+Inc.&index=1&md5=0a6d

    Business Wire ·